April 3, 2014
/PRNewswire/ -- S&P Capital IQ announced today that it has commenced
Standard & Poor's Factual Stock Report coverage on BioCorRx Inc.
BioCorRx Inc. (OTCQB: BICX) offers a comprehensive and cost-effective recovery program for the treatment of alcoholism called the Start Fresh Program which the company believes incorporates all of the essential elements for successful alcohol addiction recovery. The Start Fresh Program is designed to treat and to heal both the mind and the body. The company's alcohol rehabilitation program is a two-part program that includes the insertion of a Naltrexone Implant, by a licensed medical physician, that is believed to reduce physical cravings of alcohol; and life coaching that focuses on the mental addiction of alcoholism. BioCorRx aims to make the Start Fresh Program the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends.
The Start Fresh Program is a comprehensive treatment program used by treatment centers that is designed to significantly reduce or virtually eliminate the physical cravings for alcohol by using the time-release implant of the drug, naltrexone. BioCorRx says that, with cravings out of the way, patients can address the psychological reasons for their alcohol abuse through the company's personalized Life Coaching Program.
March 4, 2014
, BioCorRx announced the expansion of its Start Fresh Program to include treatment of opioid dependence. According to the company, naltrexone, the pharmaceutical component of the implant used by the Start Fresh Program, is FDA approved for the treatment of opioid addiction and has been used successfully for this purpose for many years all over the world. Treating this type of addiction varies however from the treatment of alcohol addiction, which is currently the main focus of the Start Fresh Program. Therefore, patients entering the new portion of the Start Fresh Program must meet certain criteria to qualify.
March 18, 2014
, the company announced that it had entered into a letter of intent to sell the exclusive license and distribution rights for its Start Fresh Program in certain Midwestern states to Fresh Start Private Midwest, LLC (Midwest). Under the terms of the pending agreement, Midwest will agree to pay BioCorRx an upfront license fee plus an ongoing upfront fee per program order in the states of
The company was formerly known as Fresh Start Private Management Inc. and changed its name to BioCorRx Inc. in
. BioCorRx Inc. is based in
Santa Ana, California
S&P Capital IQ's Factual Stock Report coverage on BioCorRx Inc.
will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit
for additional information.
About S&P Capital IQ's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.
Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.